Familial adenomatous polyposis patients have high levels of arachidonic acid and docosahexaenoic acid and low levels of linoleic acid and α-linolenic acid in serum phospholipids
Corresponding Author
Kari Almendingen
Institute of Clinical Epidemiology and Molecular Biology, Akershus University Hospital, Lörenskog, Norway
Research Institute of Internal Medicine, Rikshospitalet University Hospital, Oslo, Norway
Fax: +47-67-92-92-35.
Institute of Clinical Epidemiology and Molecular Biology, Akershus University Hospital, P.O. Box 75, NO-1474 Nordbyhagen, NorwaySearch for more papers by this authorArne T. Höstmark
Department of General Practice and Community Medicine, University of Oslo, Oslo, Norway
Search for more papers by this authorOlav Fausa
Department of Gastroenterology, Rikshospitalet University Hospital, Oslo, Norway
Search for more papers by this authorAnnhild Mosdöl
Department of Epidemiology and Public Health, University College London, London, England
Search for more papers by this authorLars Aabakken
Department of Gastroenterology, Rikshospitalet University Hospital, Oslo, Norway
Search for more papers by this authorMorten H. Vatn
Research Institute of Internal Medicine, Rikshospitalet University Hospital, Oslo, Norway
Faculty Division Akershus University Hospital, University of Oslo, Nordbyhagen, Norway
Search for more papers by this authorCorresponding Author
Kari Almendingen
Institute of Clinical Epidemiology and Molecular Biology, Akershus University Hospital, Lörenskog, Norway
Research Institute of Internal Medicine, Rikshospitalet University Hospital, Oslo, Norway
Fax: +47-67-92-92-35.
Institute of Clinical Epidemiology and Molecular Biology, Akershus University Hospital, P.O. Box 75, NO-1474 Nordbyhagen, NorwaySearch for more papers by this authorArne T. Höstmark
Department of General Practice and Community Medicine, University of Oslo, Oslo, Norway
Search for more papers by this authorOlav Fausa
Department of Gastroenterology, Rikshospitalet University Hospital, Oslo, Norway
Search for more papers by this authorAnnhild Mosdöl
Department of Epidemiology and Public Health, University College London, London, England
Search for more papers by this authorLars Aabakken
Department of Gastroenterology, Rikshospitalet University Hospital, Oslo, Norway
Search for more papers by this authorMorten H. Vatn
Research Institute of Internal Medicine, Rikshospitalet University Hospital, Oslo, Norway
Faculty Division Akershus University Hospital, University of Oslo, Nordbyhagen, Norway
Search for more papers by this authorAbstract
Familial adenomatous polyposis (FAP) provides a model of APC inactivation as an early genetic event for the ∼85% of colorectal cancers that develop from polyps. Abnormal fatty acid composition of tissues and serum phospholipids has been linked to cancer risk. Our aim was to describe the composition of fatty acids in serum phospholipids in 38 colectomized FAP patients as compared to 160 healthy subjects. Mean fatty acid intakes were similar between the groups. Colectomy was done on average 16 years prior to inclusion, and 18% were diagnosed with colorectal cancer at colectomy. The levels (weight %) of linoleic and α-linolenic acid were higher among the reference subjects (difference: 3.96, 95% confidence interval (CI) = 2.87, 5.04, and difference: 0.06, 95% CI = 0.04, 0.08, respectively), and the levels of arachidonic and docosahexaenoic acid were lower (difference: −3.70, 95% CI = −4.35, −3.06, and difference: −5.26, 95% CI = −6.25, −4.28, respectively) as compared to the FAP patients (all p ≤ 0.0001). The abnormal fatty acid composition was not related to time since colectomy, intestinal reconstruction or history of colorectal cancer for any of the fatty acids assessed. Compositional differences in the fatty acid profile of serum phospholipids have not been described before in FAP patients. Further studies are needed to confirm these findings and assess clinical significances of a possible distorted fatty acid metabolism, including a potentially different dietary need of essential fatty acids. The relevance of these findings for APC induced cancers remains unclear. © 2006 Wiley-Liss, Inc.
References
- 1 Bennett A, Civier A, Hensby CN, Melhuish PB, Stamford IF. Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut 1987; 28: 315–18.
- 2 Baro L, Hermoso JC, Nunez MC, Jimenez-Rios JA, Gil A. Abnormalities in plasma and red blood cell fatty acid profiles of patients with colorectal cancer. Br J Cancer 1998; 77: 1978–83.
- 3 Mosconi C, Agradi E, Gambetta A, Bozzetti F, Galli C. Decrease of polyunsaturated fatty acids and elevation of the oleic/stearic acid ratio in plasma and red blood cell lipids of malnourished cancer patients. JPEN J Parenter Enteral Nutr 1989; 13: 501–4.
- 4 Fernandez-Banares F, Esteve M, Navarro E, Cabre E, Boix J, Abad-Lacruz A, Klaassen J, Planas R, Humbert P, Pastor C, Gassull MA. Changes of the mucosal n-3 and n-6 fatty acid status occur early in the colorectal adenoma-carcinoma sequence. Gut 1996; 38: 254–9.
- 5 Hendrickse CW, Kelly RW, Radley S, Donovan IA, Keighley MR, Neoptolemos JP. Lipid peroxidation and prostaglandins in colorectal cancer. Br J Surg 1994; 81: 1219–23.
- 6 Neoptolemos JP, Husband D, Imray C, Rowley S, Lawson N. Arachidonic acid and docosahexaenoic acid are increased in human colorectal cancer. Gut 1991; 32: 278–81.
- 7 Busstra MC, Siezen CL, Grubben MJ, van Kranen HJ, Nagengast FM, van't VP. Tissue levels of fish fatty acids and risk of colorectal adenomas: a case-control study (Netherlands). Cancer Causes Control 2003; 14: 269–76.
- 8 Bartsch H, Nair J, Owen RW. Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers. Carcinogenesis 1999; 20: 2209–18.
- 9 Abir F, Alva S, Kaminski DL, Longo WE. The role of arachidonic acid regulatory enzymes in colorectal disease. Dis Colon Rectum 2005; 48: 1471–83.
- 10 Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004; 79: 935–45.
- 11 Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D. Identification of FAP locus genes from chromosome 5q21. Science 1991; 253: 661–5.
- 12 Yang VW, Shields JM, Hamilton SR, Spannhake EW, Hubbard WC, Hylind LM, Robinson CR, Giardiello FM. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998; 58: 1750–3.
- 13 Chu AJ, Chou TH, Chen BD. Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. Front Biosci 2004; 9: 2697–713.
- 14 Giardiello FM, Casero RA,Jr, Hamilton SR, Hylind LM, Trimbath JD, Geiman DE, Judge KR, Hubbard W, Offerhaus GJ, Yang VW. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology 2004; 126: 425–31.
- 15 Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol 2006; 12: 1336–45.
- 16 Church RD, Fleshman JW, McLeod HL. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg 2003; 90: 1055–67.
- 17 Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252–66.
- 18 Swamy MV, Cooma I, Patlolla JM, Simi B, Reddy BS, Rao CV. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. Mol Cancer Ther 2004; 3: 215–21.
- 19 Reddy BS, Patlolla JM, Simi B, Wang SH, Rao CV. Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids. Cancer Res 2005; 65: 8022–7.
- 20 Brosens LA, Iacobuzio-Donahue CA, Keller JJ, Hustinx SR, Carvalho R, Morsink FH, Hylind LM, Offerhaus GJ, Giardiello FM, Goggins M. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism. Clin Cancer Res 2005; 11: 4090–6.
- 21 Bulow S, Bjork J, Christensen IJ, Fausa O, Jarvinen H, Moesgaard F, Vasen HF. Duodenal adenomatosis in familial adenomatous polyposis. Gut 2004; 53: 381–6.
- 22 Bjorneboe A, Soyland E, Bjorneboe GE, Rajka G, Drevon CA. Effect of dietary supplementation with eicosapentaenoic acid in the treatment of atopic dermatitis. Br J Dermatol 1987; 117: 463–9.
- 23
Harvei S,
Bjerve KS,
Tretli S,
Jellum E,
Robsahm TE,
Vatten L.
Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer.
Int J Cancer
1997;
71:
545–51.
10.1002/(SICI)1097-0215(19970516)71:4<545::AID-IJC7>3.0.CO;2-U CAS PubMed Web of Science® Google Scholar
- 24 Hjartaker A, Lund E, Bjerve KS. Serum phospholipid fatty acid composition and habitual intake of marine foods registered by a semi-quantitative food frequency questionnaire. Eur J Clin Nutr 1997; 51: 736–42.
- 25 Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 2000; 102: 143–9.
- 26 Johansson L, Solvoll K, Björneboe GEA, Drevon CA. Dietary habits among Norwegian men and women. Scand J Nutr 1997; 4: 63–70.
- 27 Brustad M, Braaten T, Lund E. Predictors for cod-liver oil supplement use—the Norwegian women and cancer study. Eur J Clin Nutr 2004; 58: 128–36.
- 28 Esteve-Comas M, Nunez MC, Fernandez-Banares F, Abad-Lacruz A, Gil A, Cabre E, Gonzalez-Huix F, Bertran X, Gassull MA. Abnormal plasma polyunsaturated fatty acid pattern in non-active inflammatory bowel disease. Gut 1993; 34: 1370–3.
- 29 Esteve M, Navarro E, Klaassen J, Abad-Lacruz A, Gonzalez-Huix F, Cabre E, Ramos E, Condom E, Fernandez-Banares F, Pastor C, Humbert P, Marti-Rague J, et al. Plasma and mucosal fatty acid pattern in colectomized ulcerative colitis patients. Dig Dis Sci 1998; 43: 1071–8.
- 30 Esteve-Comas M, Ramirez M, Fernandez-Banares F, bad-Lacruz A, Gil A, Cabre E, Gonzalez-Huix F, Moreno J, Humbert P, Guilera M. Plasma polyunsaturated fatty acid pattern in active inflammatory bowel disease. Gut 1992; 33: 1365–9.
- 31 Geerling BJ, Houwelingen AC, Badart-Smook A, Stockbrugger RW, Brummer RJ. Fat intake and fatty acid profile in plasma phospholipids and adipose tissue in patients with Crohn's disease, compared with controls. Am J Gastroenterol 1999; 94: 410–7.
- 32 Andersen LF, Solvoll K, Drevon CA. Very-long-chain n-3 fatty acids as biomarkers for intake of fish and n-3 fatty acid concentrates. Am J Clin Nutr 1996; 64: 305–11.
- 33 Katan MB, van BA, Deslypere JP, Penders M, van Staveren WA. Biological markers of dietary intake, with emphasis on fatty acids. Ann Nutr Metab 1991; 35: 249–52.
- 34 Nkondjock A, Shatenstein B, Maisonneuve P, Ghadirian P. Specific fatty acids and human colorectal cancer: an overview. Cancer Detect Prev 2003; 27: 55–66.
- 35 Edes TE, Walk BE, Thornton WH,Jr, Fritsche KL. Essential fatty acid sufficiency does not preclude fat-soluble-vitamin deficiency in short-bowel syndrome. Am J Clin Nutr 1991; 53: 499–502.
- 36 Murphy J, Laiho K, Wootton S. Fat malabsorption in cystic fibrosis patients. Am J Clin Nutr 1999; 70: 943–6.
- 37 Nicholson ML, Neoptolemos JP, Clayton HA, Talbot IC, Bell PR. Increased cell membrane arachidonic acid in experimental colorectal tumours. Gut 1991; 32: 413–8.
- 38 Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 2005; 26: 449–57.
- 39 Stark KD, Mulvad G, Pedersen HS, Park EJ, Dewailly E, Holub BJ. Fatty acid compositions of serum phospholipids of postmenopausal women: a comparison between Greenland Inuit and Canadians before and after supplementation with fish oil. Nutrition 2002; 18: 627–30.
- 40 Akedo I, Ishikawa H, Nakamura T, Kimura K, Takeyama I, Suzuki T, Kameyama M, Sato S, Nakamura T, Matsuzawa Y, Kakizoe T, Otani T. Three cases with familial adenomatous polyposis diagnosed as having malignant lesions in the course of a long-term trial using docosahexanoic acid (DHA)-concentrated fish oil capsules. Jpn J Clin Oncol 1998; 28: 762–5.
- 41 Gronn M, Christensen E, Hagve TA, Christophersen BO. Effects of dietary purified eicosapentaenoic acid (20:5 (n-3)) and docosahexaenoic acid (22:6(n-3)) on fatty acid desaturation and oxidation in isolated rat liver cells. Biochim Biophys Acta 1992; 1125: 35–43.
- 42 Engler MM, Bellenger-Germain SH, Engler MB, Narce MM, Poisson JP. Dietary docosahexaenoic acid affects stearic acid desaturation in spontaneously hypertensive rats. Lipids 2000; 35: 1011–5.
- 43 Pala V, Krogh V, Muti P, Chajes V, Riboli E, Micheli A, Saadatian M, Sieri S, Berrino F. Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. J Natl Cancer Inst 2001; 93: 1088–95.
- 44
Chajes V,
Hulten K,
Van Kappel AL,
Winkvist A,
Kaaks R,
Hallmans G,
Lenner P,
Riboli E.
Fatty-acid composition in serum phospholipids and risk of breast cancer: an incident case-control study in Sweden.
Int J Cancer
1999;
83:
585–90.
10.1002/(SICI)1097-0215(19991126)83:5<585::AID-IJC2>3.0.CO;2-Z CAS PubMed Web of Science® Google Scholar
- 45 Chaudry A, McClinton S, Moffat LE, Wahle KW. Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br J Cancer 1991; 64: 1157–60.
- 46 Pandey M, Sharma LB, Singh S, Shukla VK. Erythrocyte membrane fatty acid profile and saturation index in gallbladder carcinogenesis: a case-control study. World J Surg Oncol 2003; 1: 5.
- 47 Wood CB, Habib NA, Thompson A, Bradpiece H, Smadja C, Hershman M, Barker W, Apostolov K. Increase of oleic acid in erythrocytes associated with malignancies. Br Med J 1985; 291: 163–5.